Bli medlem
Bli medlem

Du är här

2015-12-14

Phase Holographic: Phase Holographic Imaging and Boston Children's Hospital enter evaluation agreement

Phase Holographic Imaging (PHI) and Boston Children's Hospital - a
Harvard Medical School teaching hospital - have signed an agreement
to evaluate PHI's HoloMonitor® technology for applications in
cell-based cancer research. During the evaluation period, PHI will
provide Boston Children's Hospital with HoloMonitor M4.5
instrumentation and technical support.

"The agreement with Boston Children's Hospital and other opinion
leading research institutions is a key component of our strategic
marketing to establish HoloMonitor technology within preclinical
research. We look forward to the results of the evaluation and to
work with world class cancer researchers at the hospital," said CEO
Peter Egelberg.

About Boston Children's Hospital

· www.childrenshospital.org/about-us

For additional information, please contact:
Peter Egelberg, CEO
Tel: +46 703 19 42 74
E-mail: peter.egelberg@phiab.se
Web: www.phiab.se

Phase Holographic Imaging (PHI) leads the ground-breaking development
of time-lapse cytometry instrumentation and software. With the first
instrument introduced in 2011, the company today offers a range of
products for long-term quantitative analysis of living cell dynamics
that circumvent the drawbacks of traditional methods requiring toxic
stains. Headquartered in Lund, Sweden, PHI trades through a network
of international distributors. Committed to promoting the science and
practice of time-lapse cytometry, PHI is actively expanding its
customer base and scientific collaborations in cancer research,
inflammatory and autoimmune diseases, stem cell biology, gene
therapy, regenerative medicine and toxicological studies.

-----------------------------------------------------------
http://news.cision.com/se/phase-holographic/r/phase-holographic-imaging-...
http://mb.cision.com/Main/11597/9883693/456295.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.